World-Class Science

At the heart of VIB is the application of new technologies to gain new insights in understanding molecular mechanisms.

In 2011, we applied our expertise in genomics, proteomics, transcriptomics, and metabolomics to help solve 1200 diseases and disorders.

We developed technologies that can rapidly test for thousands of genetic causes of disease in a single sample.

We pioneered the use of new technologies to identify new therapeutic targets and to develop new approaches to treat disease.

We also worked on the development of new diagnostic tests and the creation of new treatments for diseases.

In 2011, we initiated a new initiative called omics@vib, which will bring together the expertise of the VIB community to solve complex biological problems.

This initiative aims to develop new technologies and new approaches to treat disease.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.

In 2011, we also initiated a new initiative called the VIB Tech Watch, which is designed to bring together the expertise of the VIB community to solve complex biological problems.
VIB is a non-profit research institute in life sciences. About 1,300 scientists conduct strategic basic research on the molecular human body, plants, and microorganisms. VIB is a member of the Flemish institute for Systems and Synthetic Biology (VIB-VAE). VIB is part of the network 'BioFlanders' and is a member of Europe's biggest research and innovation programme, Horizon 2020. The most important grant-giving body for VIB is the Flemish Government. The Flemish Government invests annually 31 million euros in VIB. VIB is also supported by annual income from its own companies. VIB has developed a number of additional sources of income such as sales of research services and other goods such as the licensed use of VIB-technology in the form of patents.

On their way to patients and consumers

VIB is an important player in the biotechnology field of Flanders. In the year 2011, VIB invested 6 million euros in its own companies. In 2011, Q-Biologicals was set up as a startup of VIB and the University of Antwerp. One of VIB’s mandates is creating new biotech companies in Flanders. VIB’s income, including the income from its own companies, increased from 9 million euros in 2010 to 12 million euros in 2011. This is an increase of 33%. This is not only a record result for VIB, it is also an excellent return in additional investments and jobs. In part thanks to VIB’s efforts, arGEN-X and Biocartis received a €50 million investment last year and therefore became outstanding biotech companies to Flanders. In total, VIB has 23 startups.

Financial Statements 2011

Structure VIB

Good Governance

The twenty or so biotech companies housed in the bio-Accelerator by 10,000 m². At the end of 2011, it was decided to expand the bio-Accelerator by 10,000 m². Bio-Accelerator by 10,000 m².

VIB is a non-profit research institute in life sciences. About 1,300 scientists conduct strategic basic research on the molecular human body, plants, and microorganisms. VIB is a member of the Flemish institute for Systems and Synthetic Biology (VIB-VAE). VIB is part of the network ‘BioFlanders’ and is a member of Europe’s biggest research and innovation programme, Horizon 2020. The most important grant-giving body for VIB is the Flemish Government. The Flemish Government invests annually 31 million euros in VIB. VIB is also supported by annual income from its own companies. VIB has developed a number of additional sources of income such as sales of research services and other goods such as the licensed use of VIB-technology in the form of patents.

On their way to patients and consumers

VIB is an important player in the biotechnology field of Flanders. In the year 2011, VIB invested 6 million euros in its own companies. In 2011, Q-Biologicals was set up as a startup of VIB and the University of Antwerp. One of VIB’s mandates is creating new biotech companies in Flanders. VIB’s income, including the income from its own companies, increased from 9 million euros in 2010 to 12 million euros in 2011. This is an increase of 33%. This is not only a record result for VIB, it is also an excellent return in additional investments and jobs. In part thanks to VIB’s efforts, arGEN-X and Biocartis received a €50 million investment last year and therefore became outstanding biotech companies to Flanders. In total, VIB has 23 startups.